Premium
Carvacrol ameliorates haematological parameters, oxidant/antioxidant biomarkers and pulmonary function tests in patients with sulphur mustard‐induced lung disorders: A randomized double‐blind clinical trial
Author(s) -
Khazdair M. R.,
Alavinezhad A.,
Boskabady M. H.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12684
Subject(s) - sulfur mustard , carvacrol , medicine , double blind , antioxidant , randomized controlled trial , lung function , pulmonary function testing , clinical trial , pharmacology , lung , chemistry , pathology , biochemistry , toxicity , food science , placebo , alternative medicine , essential oil
Summary What is known and objective In this study, the effect of carvacrol (CAR) on pulmonary function tests (PFT), haematological indices and oxidant/antioxidant biomarkers in patients with sulphur mustard (SM)‐induced lung disorders was examined. Methods Twenty patients exposed to SM 27‐30 years ago were divided into two groups and treated with either placebo (P) or CAR (1.2 mg/kg per day) (n = 10 for each group). Forced vital capacity (FVC), peak expiratory flow (PEF), total and different white blood cell (WBC), haematological parameters and oxidant/antioxidant biomarkers were measured at the baseline (step 0), one and two months (steps I and II, respectively) after starting the treatment. Results and discussion PEF was significantly increased in the CAR‐treated group in step II compared to step 0 ( P < .01). Total WBC ( P < .01) and neutrophil ( P < .05) count in the CAR‐treated group were significantly decreased in the group in steps I and II ( P < .01 for both cases) compared to step 0. The levels of thiol, superoxide dismutase and catalase in the CAR‐treated group were significantly increased ( P < .05 to P < .001) in steps I and II, but malondialdehyde significantly decreased in step II compared to step 0 ( P < .01). The percentage of total and differential WBC, oxidant/antioxidant biomarkers, FVC and PEF values following a two‐month treatment period were significantly improved in the CAR‐treated group compared to the placebo group ( P < .05 to P < .001). What is new and conclusion Two‐month treatment with CAR reduced inflammatory cells and oxidant biomarkers, whereas increased antioxidant biomarkers and improved PFT tests in SM‐exposed patients.